Xeris Biopharma (XERS) News
NASDAQ: XERSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.97+0.35 (+2.11%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
XERS news summary
We found 4 recent headlines mentioning Xeris Biopharma (XERS): 0 in the past week and 3 in the past 30 days, most often from Nasdaq, Business Wire. For price context, XERS is up 2.11% at $16.97. The most recent story, "XERS Crosses Above Average Analyst Target", was published by Nasdaq on Nov 6, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Xeris Biopharma headlines
- XERS Crosses Above Average Analyst TargetIn recent trading, shares of Xeris Biopharma Holdings Inc (Symbol: XERS) have crossed above the average analyst 12-month target price of $12.86, changing hands for $13.08/share. When a stock reaches…NasdaqXERS, HEI.A
- Xeris Biopharma Holdings, Inc. Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance to $395 Million to $405 MillionXeris Biopharma Holdings, Inc. reported its financial results for the third quarter ended September 30, 2026, with total revenue increasing 44% year-over-year to $107.2 million, primarily driven by…NasdaqXERS, WSO.B
- Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business HighlightsCHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the…Business Wire
- Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the…Business Wire